查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球巨细胞病毒治疗市场
市场调查报告书
商品编码
1311871

2023-2030 年全球巨细胞病毒治疗市场

Global Cytomegalovirus Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 200 Pages | 商品交期: 2-3个工作天内

价格

在预测期内（2023-2030 年），全球巨细胞病毒（CMV）治疗市场预计将以 5.8% 的复合年增长率增长。巨细胞病毒视网膜炎和先天性巨细胞病毒感染发病率的上升，以及对这些疾病的治疗和诊断意识的提高，是推动巨细胞病毒治疗市场增长的关键因素。例如，根据美国疾病预防控制中心（CDC）的最新数据，截至 2022 年 5 月，美国每年约有 150 名婴儿在出生时感染 CMV，其中少数婴儿会出现长期健康问题。婴儿感染 CMV 后产生的干扰素反应减弱，而成人感染 CMV 后则会产生类似的反应。

根据同一资料来源，妊娠期也有 CMV 感染和 CMV 感染再激活风险的报道，也可能导致先天性 CMV 感染。因此，疾病负担的增加预计将产生对有效治疗方案的需求，从而推动 CMV 治疗市场的增长。为开发新药而进行的临床试验研究日益增多，这可能会推动全球市场的增长。

目 录

第 1 章：报告摘要

  • 行业现状分析与增长潜力展望
  • 研究方法和工具
  • 市场细分
    • 按细分市场
    • 按地区

第 2 章：市场概述与洞察

  • 报告范围
  • 分析师洞察与当前市场趋势
    • 主要结论
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • F. Hoffmann-La Roche Ltd.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Gilead Sciences, Inc.
    • 公司概况
    • 财务分析
    • SWOT 分析
    • 近期发展
  • Teva Canada Ltd.
    • 概述
    • 财务分析
    • SWOT 分析
    • 近期发展
  • 关键战略分析

第四章：市场细分

  • 按药物类型分類的全球巨细胞病毒治疗市场
    • 西多福韦
    • 福斯奈德
    • 缬更昔洛韦
    • 更昔洛韦
  • 全球巨细胞病毒治疗市场（按应用分类
    • 干细胞移植
    • 器官移植
    • 先天性巨细胞病毒感染
    • 其他应用
  • 按销售渠道分類的全球巨细胞病毒治疗市场
    • 医院药房
    • 零售药店
    • 电子商务

第五章：地区分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • AiCuris Anti-infective Cures GmbH
  • Chimerix, Inc.
  • Clinigen Group PLC
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi Canada
  • Genentech Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Mylan N.V
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals Inc
  • Thermo Fisher Scientific, Inc.
  • Vical, Inc.
  • ViroPharma, Inc.
Product Code: OMR2027352

Title: Global Cytomegalovirus Treatment Market Size, Share & Trends Analysis Report by Drug Type (Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other Application), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and E-commerce), Forecast Period (2023-2030).

The global cytomegalovirus (CMV) treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The rising prevalence of CMV retinitis and congenital CMV infection, along with increasing initiatives to create awareness regarding treatments and diagnosis of these conditions is a key factor driving the growth of the CMV treatment market. For instance, as per the updated CDC data, as of May 2022, in the US, around 150 infants are born with CMV infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult.

As per the same source, CMV infection and the risk of reactivation of CMV infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is anticipated to create the demand for effective treatment options, thereby driving the CMV treatment market growth. The increasing clinical trial studies for the development of new drugs are likely to drive the growth of the global market.

In April 2022, the researchers have developed a calculator external link to estimate the risk that CMV infection will pass to a fetus during pregnancy. This congenital CMV infection occurs in about 20.0% to 40.0% of cases of primary maternal CMV infection. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, the calculator may support healthcare provider to counsel pregnant people with CMV. Such developments are anticipated to lower the infection rate in infants.

Segmental Outlook

The global cytomegalovirus treatment market is segmented on the drug type, application, and distribution channel. Based on the drug type, the market is sub-segmented into Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir. Based on the application, the market is sub-segmented into stem cell transplantation, organ transplantation, congenital CMV infection, and other application. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and E-commerce.

Regional Outlook

The global cytomegalovirus treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of key market players along with high healthcare expenditure. The increasing incidences of cytomegalovirus infections along with increasing awareness among consumers also play a crucial role in the regional market growth. For instance, the article published by the National Institute of Neurological Disorders and Stroke (NINDS) in July 2022 mentioned that CMV infected about 50.0% to 80.0% of adults by the age of 40 and is one of the most congenital infections in the US annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. Such an increased incidence of CMV among the North American population to create higher demand for effective treatment thereby is driving the growth of the market.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Cytomegalovirus Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing federal funding for stem cell research, which is one of the core application areas of CMV drugs. In India, the Department of Biotechnology (DBT) has supported projects for basic biology of stem cells; early and late translational research; developing gene editing technology for potential therapeutic applications and creation of animal models for various human diseases. As of 2021, the funds released by the DBT during the last three years and the current year in this area is $89.6 million.

Market Players Outlook

The major companies serving the cytomegalovirus treatment market include: F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies including funding for R&D, and new drug development, to stay competitive in the market. For instance, in September 2022, Takeda announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cytomegalovirus treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Gilead Sciences, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Teva Canada Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cytomegalovirus Treatment Market by Drug Type
    • 4.1.1. Cidofovir
    • 4.1.2. Foscarnet
    • 4.1.3. Valganciclovir
    • 4.1.4. Ganciclovir
  • 4.2. Global Cytomegalovirus Treatment Markey by Application
    • 4.2.1. Stem Cell Transplantation
    • 4.2.2. Organ Transplantation
    • 4.2.3. Congenital CMV Infection
    • 4.2.4. Other Application
  • 4.3. Global Cytomegalovirus Treatment Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. E-Commerce

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AiCuris Anti-infective Cures GmbH
  • 6.2. Chimerix, Inc.
  • 6.3. Clinigen Group PLC
  • 6.4. F. Hoffmann-La Roche AG
  • 6.5. Fresenius Kabi Canada
  • 6.6. Genentech Inc.
  • 6.7. Gilead Sciences, Inc.
  • 6.8. GlaxoSmithKline plc
  • 6.9. Merck & Co., Inc.
  • 6.10. Moderna, Inc.
  • 6.11. Mylan N.V
  • 6.12. Pfizer Inc.
  • 6.13. Takeda Pharmaceuticals
  • 6.14. Teva Pharmaceuticals Inc
  • 6.15. Thermo Fisher Scientific, Inc.
  • 6.16. Vical, Inc.
  • 6.17. ViroPharma, Inc.

LIST OF TABLES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CIDOFOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL FOSCARNET FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL VALGANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL GANCICLOVIR FOR CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR STEM CELL TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR ORGAN TRANSPLANTATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR CONGENITAL CMV INFECTION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR OTHER APPLICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 12. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR RETAIL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CYTOMEGALOVIRUS TREATMENT FOR E-COMMERCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CYTOMEGALOVIRUS TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)